Curis Inc.

12.35+0.3800+3.17%Vol 105.76K1Y Perf 1 450.12%
Nov 29th, 2023 16:00 DELAYED
BID11.51 ASK12.41
Open12.09 Previous Close11.97
Pre-Market- After-Market12.18
 - -  -0.17 -1.38%
Target Price
6.00 
Analyst Rating
Strong Buy 1.50
Potential %
-51.42 
Finscreener Ranking
★★★     49.48
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★+     53.27
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★+     40.61
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
52.78 
Earnings Rating
Sell
Market Cap72.66M 
Earnings Date
2nd Nov 2023
Alpha0.03 Standard Deviation0.66
Beta3.14 

Today's Price Range

12.0612.99

52W Range

3.8020.00

5 Year PE Ratio Range

-6.60-2.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
47.37%
1 Month
194.75%
3 Months
2 045.21%
6 Months
1 440.67%
1 Year
1 450.12%
3 Years
751.72%
5 Years
1 336.05%
10 Years
-22.81%

TickerPriceChg.Chg.%
CRIS12.350.38003.17
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
7.40
7.70
0.05
0.08
-13.00
Leverage Ratio 2.00
ProfitabilityValueIndustryS&P 500US Markets
96.70
-525.80
-524.10
-376.60
-
RevenueValueIndustryS&P 500US Markets
7.28M
0.08
2.88
4.09
Earnings HistoryEstimateReportedSurprise %
Q03 2023-2.32-2.138.19
Q02 2023-2.40-2.400.00
Q01 2023-2.20-2.40-9.09
Q04 2022-2.80-2.4014.29
Q03 2022-3.40-2.8017.65
Q02 2022-3.40-3.400.00
Q01 2022-0.17-0.18-5.88
Q04 2021-0.13-0.15-15.38
Earnings Per EndEstimateRevision %Trend
12/2023 QR-2.0311.74Positive
12/2023 FY-9.091.94Positive
3/2024 QR-2.095.00Positive
12/2024 FY-5.2038.10Positive
Next Report Date-
Estimated EPS Next Report-2.32
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume105.76K
Shares Outstanding5.88K
Shares Float5.18M
Trades Count1.23K
Dollar Volume1.32M
Avg. Volume158.11K
Avg. Weekly Volume140.12K
Avg. Monthly Volume162.54K
Avg. Quarterly Volume171.66K

Curis Inc. (NASDAQ: CRIS) stock closed at 12.35 per share at the end of the most recent trading day (a 3.17% change compared to the prior day closing price) with a volume of 105.76K shares and market capitalization of 72.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 28 people. Curis Inc. CEO is James E. Dentzer.

The one-year performance of Curis Inc. stock is 1450.12%, while year-to-date (YTD) performance is 2145.45%. CRIS stock has a five-year performance of 1336.05%. Its 52-week range is between 3.8 and 20, which gives CRIS stock a 52-week price range ratio of 52.78%

Curis Inc. currently has a PE ratio of -1.00, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of 8.48, a price to cashflow ratio of 36.40, a PEG ratio of -, a ROA of -43.90%, a ROC of -65.89% and a ROE of -82.51%. The company’s profit margin is -%, its EBITDA margin is -524.10%, and its revenue ttm is $7.28 Million , which makes it $0.08 revenue per share.

Of the last four earnings reports from Curis Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-2.32 for the next earnings report. Curis Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Curis Inc. is Strong Buy (1.5), with a target price of $6, which is -51.42% compared to the current price. The earnings rating for Curis Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Curis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Curis Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.60, ATR14 : 1.19, CCI20 : 193.10, Chaikin Money Flow : -0.13, MACD : 1.59, Money Flow Index : 82.01, ROC : 92.75, RSI : 87.41, STOCH (14,3) : 92.35, STOCH RSI : 1.00, UO : 50.31, Williams %R : -7.65), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Curis Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
1 (33.33 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Moderate Buy
1.67
Moderate Buy
1.67

Curis Inc.

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

CEO: James E. Dentzer

Telephone: +1 617 503-6500

Address: 4 Maguire Road, Lexington 02421, MA, US

Number of employees: 28

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

46%54%

Bearish Bullish

53%47%

Bearish Bullish

58%42%

 

TipRanks News for CRIS

Fri, 29 Sep 2023 15:36 GMT Buy Rating for Curis (CRIS) Amidst Reverse Stock Split and Revised Launch Estimates for Key Product, Emavusertib

- TipRanks. All rights reserved.

Fri, 07 Jul 2023 10:15 GMT Curis (CRIS) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits